Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

Net proceeds of approximately $117.1 million are intended to fund NXC-201 development, working capital and general corporate purposes.

Rhea-AI Summary

Immix Biopharma (IMMX) closed its previously announced $125 million underwritten offering of common stock, adding funding for its development plans.

The company sold 11,363,637 shares at $11.00 per share and received approximately $117.1 million in net proceeds after underwriting discounts, commissions and other offering expenses. Immix intends to use the proceeds to fund NXC-201 development, working capital and general corporate purposes. U.S. biotechnology institutional investors and mutual funds participated, and J.P. Morgan served as sole book-running manager.

3 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointCompleted offering delivered approximately $117.1 million in net proceeds after discounts, commissions and offering expenses. 16% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Immix intends to fund NXC-201 development with offering proceeds.
• Minor pointOffering attracted participation from U.S. biotechnology institutional investors and mutual funds.

Negative

• Major pointIssuance of 11,363,637 common shares at $11.00 per share dilutes existing holders.

News Explained

Immix received approximately $117.1 million in net proceeds from the completed offering.

Immix Biopharma has completed a common-stock sale of 11,363,637 shares; absent offsetting changes, the additional shares reduce existing holders’ percentage ownership.

The $125 million gross offering equals 969.3 days of second-quarter 2026 operating cash outflow at the reported rate; this is a backward-looking comparison, not a forecast of funding duration.

Sources and calculations

• Immix Biopharma offering-closing release (2026-09-30)
• Second-quarter 2026 fundamentals (2026Q2)
• Dilution definition (undated)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $125,000,000 / ($11,735,505 / 91) = 969.3 days

Key Figures

Offering size: $125 million Shares offered: 11,363,637 shares Offering price: $11.00 per share +1 more

Offering size

$125 million

Underwritten offering

Shares offered

11,363,637 shares

Common stock

Offering price

$11.00 per share

Public offering

Net proceeds

Approximately $117.1 million

After underwriting discounts, commissions and other offering expenses

Previous Offering Reports

1 past event · Latest: Sep 29

Same Type 1 event

1. Sep 29

   Offering pricing

   24h Move

   -8.1%

   Pricing terms established the same underwritten offering that closed in this announcement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten offering, shelf registration statement, form s-3, prospectus supplement, +1 more

5 terms

underwritten offering financial

"closing of its previously announced underwritten registered offering"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"a shelf registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A prospectus supplement and accompanying prospectus describing the terms"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

car-t medical

"chimeric antigen receptor T (CAR-T) cell therapy NXC-201"

CAR-T is a type of cancer therapy that reprograms a patient’s own immune cells to seek and destroy specific cancer cells, like teaching guard dogs a new scent to track intruders. It matters to investors because CAR-T treatments can command high prices, drive strong revenue for successful developers, and carry regulatory and manufacturing risks that can sharply affect a company’s valuation and long-term growth prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Financing includes leading U.S. biotechnology institutional investors and mutual funds –

LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $117.1 million.

Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes.

J.P. Morgan acted as the sole book-running manager for the offering. The offering included participation from leading U.S. biotechnology institutional investors and mutual funds.

The shares of common stock described above were offered and sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-292665), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 9, 2026, and declared effective on January 22, 2026. A prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC and is available on the SEC’s website located at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus related to this offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Contacts

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com 

Company Contact

Gabriel Morris, CFO
irteam@immixbio.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Immix Biopharma raise in its completed common stock offering?

Immix Biopharma closed a $125 million offering and received approximately $117.1 million in net proceeds. It sold 11,363,637 common shares at $11.00 per share; net proceeds reflect underwriting discounts, commissions and other offering expenses.

What will Immix Biopharma use the offering proceeds for?

Immix intends to use the net proceeds to fund NXC-201 development, working capital and general corporate purposes.